OPIOIDS AND PROTEASE INHIBITORS - DEXTROPROPOXYPHENE (PROPOXYPHENE)
Ritonavir is predicted to increase the effects of dextropropoxyphene. Other protease inhibitors may also be expected to interact similarly but there seems little documented about these effects in practice.
The UK manufacturer of ritonavir contraindicates its use with dextropropoxy- phene as extremely raised dextropropoxyphene levels may occur, which would increase the risk of serious adverse events (e.g. respiratory depression). However, the US manufacturer only suggests that a dose decrease may be needed.
The UK manufacturer of ritonavir contraindicates its use with dextropropoxy- phene as extremely raised dextropropoxyphene levels may occur, which would increase the risk of serious adverse events (e.g. respiratory depression). However, the US manufacturer only suggests that a dose decrease may be needed.